Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They were going to have the call either way, so personally I don't see the need to tout the call unless you have something to tout. It will be what it will be and I'm hopeful for good news.
ACAD Data tomorrow morning...
http://finance.yahoo.com/news/acadia-pharmaceuticals-host-conference-call-210100573.html
ACAD data tomorrow PM, conference call to follow.
http://finance.yahoo.com/news/acadia-pharmaceuticals-host-conference-call-210100573.html
Me thinks you don't announce your announcing results unless they are good. You would just release them.
The company clearly stated they would release the data Pre-market with a conference call to follow. They also stated they fully expect the data to be released before the end of November, so, given this info it would seem reasonable to conclude tomorrow, Wed, Thursday or Friday Pre-market. I hope tomorrow as I was hopeful it would be today.
I don't see any of those higher buys on my L2.
Very light volume.
The reason it has a chance to explode is because the market cap is low. The sales potential alone for this drug are 3-5 times the current market cap which means it can explode.
Sheff what are your thoughts on how the market will react to positive data for CHTP. The FDA has already said they can't use the data for approval purposes, at least not without another trial to follow. Positive data would be nice, but it would seem to come with no leverage for the company short term.
If you like down hill roller coasters...than yes WEEEEEEEEEEEE!!!
Chris asked that I post this PM, this is one thing I didn't know about options.
My Question:
Chris am I correct in assuming that even though in your twinkie example the contract cost was only $15, in order to actually buy that contract, you have to have funds available to purchase the contract + premium, so in other words 100 * $30 + $15 = $3015.00. Right? You can't execute that trade without having the total funds that you would need to buy the stock outright.
His Answer:
nope, you would need all those funds if you were shorting calls and puts. All you need is the funds to cover the contracts + commission. for $15, the listed price would have been $0.15 (x 100 contracts)
in the twinkie example (only bc there isnt a liquid market) you would need the funds to buy the 100 boxes, but in a liqiud market you can just sell the contract for the exact same profit, and that is what everybody does.
They won't release before next week...wouldn't make any sense at this point. Unless it was bad news...a Friday release might make sense.
ACAD will go as the data goes...puts is a strategy, so are calls...peeps gotta trade how they feel comfortable.
ACAD - $2.24 running hard today. EOM
Looks like the wall at $1.95 has been cleared, lets see if we can get this to push past $2.00 today.
I think he was asking who gets to decide when a halt is lifted...the company or the SEC? Nice pop in LGND today.
ACAD - If you are a fan of T/A and charts, low of $1.82 today is a classic set up for a 200 day MA bounce. Not sure how high as there is limited time before data release. But, might provide an opportunity for a nice trade before data release.
The last didn't exactly end disastrously...it didn't meet expectations, but lets be keep some perspective.
Many have been in this since $1.00, they don't want to see profits erode, they were hoping for a run up too. News hasn't leaked.
I'm very confident, this drug is safe and effective and the FDA wants this on the market. They conceded a lot in the design of this trial. Nothing is a given, but pps manipulation leading up to results doesn't bother me a bit. If this was trading near $2.50 everyone would be happy but if results are negative the result will be the same whether the stock is $2.50 or $1.85...it will be a stock under $1.00, but if results are good, the pps will move north quickly, no matter how it is trading right now.
Let's keep some perspective on this board at least...ACAD is NOT in a free fall.
someone might be a tad sensitive to minimal price movement in bio-tech stocks. Be confident in what you own or don't own it.
PWEID finally tanking...was weird to see that one still up even after new pick announced.
Take a look at the chart for AMRN before their news...people said the same thing...it happens, A LOT!
Decent options action for ACAD in Nov and Dec for 2.50 and 5.00 calls.
I like DVAX too, although the 3/4 billion market cap on this one leads me to believe upside potential is fairly limited.
I really would hate to see the $2.15 support level give way though...
Reminds me of how AMRN traded leading up to catalyst...
Your opinion is noted...my opinion is that data will be released the week of the 26th.
Many of the other boards I follow where ACAD is discussed, the general consensus seems to be the week of the 26th. It makes sense, they aren't going to release the week of Thanksgiving, so that leaves next week or the week of the 26th. If it was going to be next week, I think they could have said at the CC, we expect data to be released by the middle of November, but they reiterated by the end of the Month.
Most think the week of November 26th.
ATHX - $1.00 current pps. DD for the board, potential good run-up candidate:
P2 results due in March 2013, currently trading at $1.00. It is a nasdaq stock (not a pinky). They just finished a 19 million dollar raise, so they shouldn't need to raise before results. Also, sitting at 52 week lows. Some DD and data about the trial linked below:
http://ir.athersys.com/secfiling.cfm?filingid=1193125-12-352343
http://seekingalpha.com/article/305875-athersys-multistem-pi-data-for-acute-myocardial-infarction
In early 2013, Athersys, Inc. (ATHX) plans to release initial results of a collaborative study with Pfizer (PFE) to treat ulcerative colitis using MultiStem, its flagship product derived from stem cells. Ulcerative colitis affects more than 2.3 million people in the United States, with average healthcare costs estimated to be $1.7 billion. There is also no cure for ulcerative colitis. Current treatments, including surgery in some cases, are not always effective and may only provide temporary relief for symptoms.
The progress these companies are demonstrating in finding safe solutions to previously incurable diseases is impressive. Biotech companies at the clinical stage certainly present moderate risk as they do not have a commercialized product pipeline. However, it is certainly worth monitoring the status of these clinical trials over the next three to six months as products move closer to commercialization.
Not a very objective article at all. I've come to expect nothing less from him though, I'll leave it at that...
I agree Sheff...I really think the FDA and the company have designed this study to give them the best chance for positive results. I think since the drug is very safe, the FDA wants this as bad as ACAD does.
You can say that again...I also think this might be Friday Drop Day and we see a 50% dip. I'll be watching for that today or next week and maybe taking a position for the next run. Have to see the volume on the drop before I decide.
Yeah looks to be the case. I just found this and only heard the news on tv before this, tv news just said markets shut down.
http://money.cnn.com/2012/10/28/investing/hurricane-sandy-stock-exchange/index.html?source=cnn_bin
Market is shutting down due to storm in north east.
EDIT: Sheff what are your thoughts on CHTP...currently trading at $1.46 and has made a nice move over the past couple of weeks.
I know they are currently in a study, but that study won't be enough for approval from the FDA, so I'm wondering if good results are still a big catalyst for this company. In the end they won't mean much, other than to shape the next study.
I'm thinking that maybe the FDA "faster pathway" might have something to do with the recent pps increase. CHTP's drug would seem to fit into a socially beneficial drug category.
Just sold out of TAGG for a nice profit over the past couple of days. Been a solid play so far.